Amgen Inc (HKSE:04332)
HK$ 1761 0 (0%) Market Cap: 1.17 Til Enterprise Value: 1.57 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 92/100

Amgen Inc Call from European Society for Medical Oncology 2021 Congress Transcript

Sep 16, 2021 / 12:30PM GMT
Release Date Price: HK$1850
Operator

My name is Christie, and I will be your conference facilitator today for Amgen's Conference Call from the European Society for Medical Oncology 2021 Virtual Congress. (Operator Instructions)

I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.

Arvind Sood
Amgen Inc. - VP of IR

Thank you, Christie. Good morning, everyone. Thanks for joining us this morning.

So we presented important data at the ESMO meeting yesterday, looking at a combination of our KRAS G12C inhibitor LUMAKRAS with our EGFR inhibitor Vectibix, or panitumumab, in advanced colorectal cancer. We continue to lead with the largest and most comprehensive development program in patients with the KRAS G12C mutation. We look forward to going through this data in additional detail this morning, and we'll also use this opportunity to discuss our broader emerging oncology portfolio.

Joining me this morning are Dr. David Reese, our Executive Vice President of R&D; and Dr. PK Morrow, our Vice President for Global

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot